Objectives. Targeting the granulocyte-macrophage colony-stimulating factor (GM-CSF) pathway holds great potential in the treatment of inflammatory diseases. Mavrilimumab, a human monoclonal GM-CSF receptor-a antibody, has demonstrated clinical efficacy in RA. Our current study aimed to elucidate mechanisms of action and identify peripheral biomarkers associated with therapeutic responses of GM-CSF antagonism in RA.
Introduction
RA is a chronic inflammatory disorder that affects the body's joints and the extra-articular tissues of the skin, heart and muscles. Increased flow of white blood cells into the synovium leads to inflammation that causes acute swelling and the destruction of cartilage and bone tissue. Both the innate and adaptive immune systems are activated and contribute to the inflammatory process in RA. Dysregulated immune cells release inflammatory and toxic mediators such as TNF, IL-6, GM-CSF and MMPs, which will in turn attract other inflammatory cells to the site of inflammation or mediate tissue damage [1] . Among these mediators, cytokines play a combinatorial role in mediating the overlapping innate and adaptive immune responses associated with RA disease onset and persistence [2] . Anti-cytokine therapies have transformed treatment for RA patients with the introduction of TNF and IL-6 inhibitors to the clinic. However, unmet therapeutic needs remain for the significant proportion of patients who neither tolerate nor respond to these therapies.
GM-CSF is a monomeric glycoprotein that functions as a cytokine and a haemopoietic growth factor for the proliferation of myeloid cells from bone-marrow progenitors. It acts on mature leucocytes to enhance antigen presentation, induce phagocytosis and promote leucocyte chemotaxis and adhesion [3] . Evidence indicates that GM-CSF plays important roles in the development and pathogenesis of RA. Elevated GM-CSF levels are evident in plasma, SF and synoviocytes of RA patients [4] , and GM-CSF administration has been reported to exacerbate RA disease manifestation [5] . Mavrilimumab is a fully human mAb targeting the a-subunit of GM-CSF receptor (GM-CSFRa) for potential treatment of RA and other inflammatory diseases. Phases 1, 2a and 2b clinical trials evaluating mavrilimumab have demonstrated safety and potential beneficial effects in RA patients [68] . This novel GM-CSF targeting therapy may be an additional option for patients who fail to respond to current treatments or who experience serious adverse events [9] .
Given the complex molecular pathogenesis and highly heterogeneous clinical landscape, the value of clinical biomarkers has been increasingly recognized for the implementation of targeted therapies in RA. Integrated analysis of biomarkers and clinical endpoints elucidates treatment modes of action, which helps in our understanding of pathophysiological pathways and clinical disease manifestation and reveals novel insights leading to further discoveries. In this study, we analysed multiple serum proteomics markers and profiled whole blood gene expression patterns before and post-administration of placebo (PBO) or mavrilimumab to elucidate the mechanism of action of anti-GM-CSF therapy and the role of the GM-CSF pathway in RA patients. Our results demonstrated significant suppression of macrophage and T cell pathways by mavrilimumab, and identified pharmacodynamic biomarkers associated with clinical response to the GM-CSF blockade therapy in RA.
Methods

Study design, subjects and clinical measurements
In a multicentre phase 2b, double-blind, parallel-group study, patients with adult-onset RA were randomized 1:1:1:1 to s.c. mavrilimumab (150, 100, 30 mg) or PBO every 2 weeks in combination with a stable dose of MTX (7.525.0 mg/week) for 24 weeks, followed by a 12-week safety follow-up period or transfer to a long-term open label extension study (EARTH EXPLORER 1; NCT01706926). Of 326 patients randomized, 305 completed the study. Disease Activity Score 28 (DAS28)CRP was significantly reduced from baseline for mavrilimumab compared with PBO (P < 0.001), and ACR20 response was achieved by significantly more patients treated by mavrilimumab than PBO (P < 0.001). The study was approved by Institutional Review Boards or independent ethics committees. All patients provided written informed consent. The detailed study design, patient characteristics, treatment safety and efficacy profiles have recently been published [8] .
Serum proteomics profiling
Sera from RA patients at baseline and various time points after mavrilimumab and PBO administration were kept frozen at À80 C before shipment to Nordic Biosciences (Herlev, Denmark) and Crescendo Bioscience (San Francisco, CA, USA) for the measurement of serum proteomic markers. Our previous results have demonstrated mavrilimumab-induced suppression of serum fragment of type I collagen (C1M), a marker of tissue damage associated with structural progression [8] . Here, we measured another extracellular matrix turnover marker, the 7S domain of collagen type IV (P4NP 7S) [10] in the sera of RA patients and 20 healthy controls by ELISA at Nordic Biosciences. Treatment with high doses of mavrilimumab also induced early and sustained reductions in a multibiomarker disease activity (MBDA) score [8] . The MBDA score consists of 12 inflammatory markers involved in different aspects of RA pathophysiology, including IL-6, CRP, serum amyloid A, EGF, VEGFA, vascular cell adhesion molecule 1, leptin, TNF receptor 1 (TNFRSF1A), resistin, cartilage glycoprotein 39 (CHI3L1), MMP1 and MMP3 [11] . In the current study, we analysed those individual markers in association with clinical response to better understand the mechanism of action of mavrilimumab treatment. Furthermore, we measured serum levels of macrophage-derived chemokine (CCL22) by Meso Scale Discovery platform, and a T cell activation marker, IL-2 receptor a (IL2RA) by ELISA at Crescendo Bioscience, both of which have been shown to be modified by mavrilimumab in a previous study [12] .
Whole genome microarray study PAXgene Blood RNA Tubes (Qiagen, Valencia, CA, USA) were collected from RA subjects at baseline, days 85 and 169 after 150 mg mavrilimumab or PBO administration. Total RNA was extracted using the PAXgene Blood RNA kit (Qiagen), and biotin-labelled cRNA was generated and fragmented for hybridization on Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays (Affymetrix, Santa Clara, CA, USA). The general procedures for sample processing and data analysis for microarray studies have been described previously [13] .
Data analysis
The KruskalWallis H test and MannWhitney U test were used to compare continuous unpaired variables, and Fisher's exact test was used for discrete variables. Paired pre-and post-treatment comparison was carried out by the Wilcox signed rank test. Multiple comparison problems were controlled by the BenjaminiHochberg (BH) adjustment.
We performed differential gene expression analysis by significance analysis of microarrays (SAM) [14] . Canonical pathways enriched in the differentially expressed gene sets were identified by ingenuity pathway analysis. Moreover, a modular analysis approach was used to analyse the effects of mavrilimumab on 28 modules of transcripts that demonstrated coordinated regulation of expression in whole blood across a set of inflammatory and infectious diseases [15] . For each module, we determined what fraction of the probes were significantly upregulated or down-regulated based on significance analysis of microarrays (BH P < 0.05). Fisher's exact test was used to measure the significance in distribution of up-/ down-regulated probes in each module.
Results
P4NP 7S and mavrilimumab treatment in RA
We measured type IV collagen formation marker in 207 RA patients receiving placebo, 100 mg or 150 mg mavrilimumab, along with 20 age-, gender-and race-matched healthy controls (P > 0.05). The P4NP 7S level was significantly higher at baseline in severe RA patients (DAS28CRP > 5.1) than moderate patients (3.2 < DAS28CRP 4 5.1) and healthy controls (supplementary Fig. S1 , available at Rheumatology Online). RA patients with high P4NP 7S concentration at baseline demonstrated significantly higher inflammatory biomarker (CRP and ESR) levels and disease activity scores such as DAS28CRP, DAS28ESR and the Health Assessment Questionnaire Disability Index (HAQ-DI) than those with low P4NP 7S level, while there was no significant difference in demographic and concurrent medication profiles between two groups of patients (Table 1 ). High serum P4NP 7S level was associated with high modified Total Sharp Score (mTSS) including worse joint space narrowing and joint erosion, suggesting the value of P4NP 7S as a structural damage marker in RA. Post-treatment assessment indicated differential regulation of serum P4NP 7S levels by mavrilimumab and PBO (Fig. 1A) . Mavrilimumab at 150 mg induced significant suppression of P4NP 7S at days 85 and 169 compared with pre-dose (P < 0.05), while no change was observed post-administration of 100 mg mavrilimumab or PBO. The reduction was significantly different between ACR20 responders and non-responders at both early and late time points after administration of a high dosage of mavrilimumab (Fig. 1B) . In contrast, although a type I collagen degradation marker has been shown to be suppressed by 100 and 150 mg mavrilimumab [8] , the reduction of C1M was associated with clinical response only at late time point after 100 mg mavrilimumab treatment (supplementary Fig.  S2 , available at Rheumatology Online).
Effects of mavrilimumab on serum protein markers
Our previous results showed mavrilimumab-induced suppression of a composite MBDA score based on serum levels of 12 individual proteins [8] . Detailed inspection of the 12 constituents indicated significant changes of IL-6, serum amyloid A and CRP levels after administration of mavrilimumab. Higher dosages of mavrilimumab induced greater protein suppression than PBO and a low dosage of mavrilimumab ( Fig. 2A and B) . Those three proteins may be the main contributors to the MBDA suppression we have observed earlier. Furthermore, we measured serum levels of two macrophage and T cell markers before and after mavrilimumab and PBO treatments in this study. Our results demonstrated significant difference in CCL22 and IL2RA changes after administration of PBO and different dosages of mavrilimumab ( Fig. 2C and D) . Both 100 and 150 mg mavrilimumab induced an early and sustained suppression of CCL22 and IL2RA serum levels (P < 0.05), while PBO or 30 mg mavrilimumab had no impact on the two markers. We then assessed the correlation between serum biomarker changes and clinical responses after mavrilimumab treatments. The decrease of IL-6 levels was showed to be associated with ACR20 response status. Rapid IL-6 reduction was sustained in ACR20 responders but not non-responders in 100 or 150 mg mavrilimumab-treated patients ( Fig. 2E and F) .
Regulation of peripheral transcripts by mavrilimumab
To investigate downstream effects of GM-CSF antagonism on RA pathophysiological pathways, we compared whole blood microarray data between 150 mg mavrilimumab and PBO-treated patient cohorts at different time points. While no differentially expressed transcripts were found at baseline, we identified 980 and 382 probesets with lower expression in mavrilimumab-treated patients compared with PBO-treated patients at days 85 and 169 post-administration, respectively (BH P < 0.05). Ingenuity pathway analysis identified the role of macrophages, fibroblasts and endothelial cells in RA as one of the top enriched pathways in mavrilimumab-suppressed transcripts. In addition, mavrilimumab suppressed the triggering receptor expressed on myeloid cells 1 signalling, which is involved in the chronic inflammation of RA [16] . Interestingly, IL-17A signalling in fibroblasts and IL-22 signalling pathways were significantly enriched in the differentially expressed transcripts at day 169 post-administration of PBO and mavrilimumab, suggesting a
FIG. 1 Suppression of type IV collagen marker by mavrilimumab
(A) Significant suppression of P4NP 7S by 150 mg mavrilimumab (n = 73) but not placebo (n = 49) or 100 mg mavrilimumab (n = 70) treatments based on Wilcox signed rank test. (B) P4NP 7S reduction was significantly different between ACR20 responders (n = 56) and non-responders (n = 17) at both early and late time points post-administration of 150 mg mavrilimumab based on Mann-Whitney U test. Percentage changes from baseline shown as geometric mean (S.E.). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
FIG. 2 Suppression of serum protein markers by mavrilimumab
(AD) Post-treatment changes of IL-6, serum amyloid A (SAA), CCL22 and IL2RA from baseline were significantly different in four groups of patients receiving placebo (n = $4659), 30 mg (n = $5261), 100 mg (n = $5260) or 150 mg mavrilimumab (n = $5664) based on KruskalWallis H test. Higher reduction was observed after treatment of higher doses of mavrilimumab (100 and 150 mg) than low dose of mavrilimumab (30 mg) or placebo. (E) IL-6 reduction induced by 100 mg mavrilimumab was significantly different between ACR20 responders (n = 35) and non-responders (n = 26) based on MannWhitney U test. (F) Significant difference in IL-6 suppression by 150 mg mavrilimumab in ACR20 responders (n = 46) and non-responders (n = 20) based on MannWhitney U test. Percentage changes from baseline are shown as geometric mean (S.E.). *BH P < 0.05, **BH P < 0.01, ***BH P < 0.001, ****BH P < 0.0001. suppressive effect of mavrilimumab on TH17 cells of RA patients (supplementary Fig. S3 , available at Rheumatology Online).
We next used a modular analysis method to profile distribution of up-/down-regulated probes post-administration of mavrilimumab or PBO in 28 gene expression modules [15] . Recently, this approach has been used to capture reproducible gene expression changes in anti-TNF responders [17] . Our results demonstrated consistent changes in 12 modules in ACR20 responders after administration of mavrilimumab, while very few changes were observed in ACR20 non-responders (Fig. 3) . Similar modular gene expression patterns have been observed earlier in three groups of anti-TNF responders, including decrease of platelets (M1.2), myeloid lineage (M1.5, M2.6) and inflammation modules (M3.2, M3.3), along with increase in B cells (M1.3), major histocompatibility complex and ribosome (M1.7, M2.4), T cells (M2.8) and two undetermined modules (M2.11, M3.7) [17] . In contrast, neither ACR20 responders nor ACR20 non-responders in the PBO-administered patients exhibited consistent changes for the modules regulated by mavrilimumab, with the exception of the undetermined modules M2.11 and M3.7.
Recently, a signal transducer and activator of transcription 3 (STAT3) target-enriched gene signature has been identified in circulating CD4 + T cells of RA patients [18] .
Our results demonstrated significant suppression of STAT3 along with its inducible transcripts including suppressor of cytokine signalling 3, B cell lymphoma 3-encoded protein and retinoic acid receptor a [19] in mavrilimumab-treated ACR20 responders (BH P < 0.05), but not non-responders or PBO-administered patients. A heatmap of post-treatment changes also showed a clear distinction in the suppression of multiple myeloid cell-associated transcripts by mavrilimumab, such as pattern recognition receptor CD14, integrin a-X or CD11c, IL-8 receptor a (CXCR1), chemokine receptor 1 (CCR1), neutrophil gelatinase-associated lipocalin (LCN2 or NGAL), NAD + kinase (NADK) and IL-1B between mavrilimumab-induced ACR20 responders (BH P < 0.05) and non-responders at both days 85 and 169 after treatment (Fig. 4) . The programmed death-ligand 1 (PD-L1 or CD274)/programmed death 1 (PD-1) pathway plays an important role in the regulation of T cell response within the rheumatic joint, and PD-L1 has been shown to display increased expression in macrophages infiltrating rheumatoid synovium [20] . Mavrilimumab induced significant suppression of PD-L1 transcript in ACR20 responders only at day 169 post-administration, while significant changes of PD-L1 were seen in both responders and non-responders at day 85 after mavrilimumab treatment (BH P < 0.05). The possible inhibition of the PD-L1/PD-1 pathway by mavrilimumab may reflect the deactivation of both macrophages and T cells post-administration of mavrilimumab, particularly in ACR20 responders. In addition, suppression of MMP9 and MMP25 may contribute to reduced degradation of extracellular matrix evidenced by P4NP 7S and C1M inhibition in mavrilimumab-treated responders. Two protein citrullinating enzymes, peptidyl arginine deiminase type 2 (PAD2) and type 4 (PAD4), showed decreased expression in ACR20 responders, which is consistent with the trend of reduction in citrullinated vimentin fragment after the administration of mavrilimumab (Mortensen et al. manuscript under review).
Discussion
Infiltration of activated macrophage and other myeloid cells in rheumatoid synovium perpetuate inflammatory reactions and tissue damage through release of cytokines, chemokines, reactive oxygen and nitrogen intermediates, proteases and microparticles [21] . Synovial macrophages produce many inflammatory mediators, such as TNF, IL-1 and IL-6, which have been targeted for RA treatment. IL-6 activates a cascade of inflammatory events leading to MMP-mediated degradation of cartilage matrix and activation of osteoclasts. This stimulates the proliferation and differentiation of T lymphocytes into Th17 cells, and thus inhibition of IL-6 function has been reported to induce a significant decrease of Th17 cells in RA [22] . Neutrophils possess the greatest cytotoxic potential of all cells implicated in the pathology of RA. They also regulate the function of macrophages, T cells and other immune cells to orchestrate the progress of inflammation. Recently, neutrophils from RA patients have been found to have an enhanced tendency to form neutrophil extracellular traps (NETs) containing citrullinated proteins, which may be a source of autoantigens driving the autoimmune processes underlying RA pathology [23, 24] . NADPH-dependent generation of ROS and histone citrullination by PAD4 are essential for NET formation [25] . Our gene expression study demonstrated suppression of multiple macrophage-and neutrophil-associated transcripts such as CD14, triggering receptor expressed on myeloid cells 1, CXCR1 and CCR1, especially in responders after administration of mavrilimumab. Decreased NADK and PAD4 expression may reduce the NADPH level [26] and protein citrullination, resulting in the reduction of NET formation. Gene expression modules of the myeloid lineage were suppressed by mavrilimumab in ACR20 responders but not non-responders (Fig. 3) . For clinical responders, the modular gene expression changes do not seem to be unique to mavrilimumab, which may be caused by the small number of modules used in the modular analysis approach. However, a true comparison of anti-TNF and anti-GM-CSFR therapies could only be achieved by head to head comparison in a clinical trial. Classical pathway analysis also indicated suppression of a macrophage-associated pathway by mavrilimumab (supplementary Fig. S1 , available at Rheumatology Online). Serum proteomics demonstrated mavrilimumabinduced suppression of CCL22, a macrophage-derived chemokine whose production may be potentiated by GM-CSF [27] . These results suggest that blockade of GM-CSFR on myeloid cells suppresses macrophage and neutrophil activation in association with clinical response to mavrilimumab in RA patients.
FIG. 3 Transcriptional module change in ACR20 responders or non-responders after administration of placebo or mavrilimumab
The first two sets of bars in each module indicate changes at day 85 (R: n = 19; NR: n = 33) and day 169 (R: n = 18; NR: n = 46) after placebo treatment, while the last two sets of bars show changes at day 85 (R: n = 53; NR: n = 18) and day 169 (R: n = 52; NR: n = 17) after 150 mg mavrilimumab treatment. A detailed description of each module can be found in the original publication on modular transcriptional analysis framework [17] . The height of bars above or below the horizontal line shows the fraction of probes significantly increased or decreased within each module, respectively. Solid bars: P < 0.001; darkly shaded bars: P < 0.01; lightly shaded bars: P < 0.05; open bars: P > 0.05. R: responders; NR: non-responders.
Cytokine inhibition not only rapidly reduces or blocks inflammation and joint destruction of RA, but also affects upstream events through feedback mechanisms [23] . Our gene expression results suggest that GM-CSF inhibition may suppress T helper cell activation while restoring overall T cell homeostasis in RA patients. RA patients had a marked contraction of the T cell receptor repertoire, and fewer naïve T cells than healthy controls [28, 29] . Multiple CD3 + T cell-associated transcripts have been shown to be underexpressed in peripheral blood of RA patients [30] . Mavrilimumab induced upregulation of the T cell gene expression module may reflect an improvement of the T cell homeostasis in RA patients. On the other hand, our results demonstrated significant suppression of serum IL2RA levels, peripheral transcripts enriched in CD4 + T cell STAT3 activation and IL-17/IL-22 signalling pathways, suggesting the inhibition of CD4 + T cell activation including Th17 cells after blockade of the GM-CSF pathway. GM-CSFRa is expressed on myeloid cells and some non-haemopoietic cells, such as endothelial cells, but not T cells [31] . The effects of GM-CSF on TH17-mediated inflammation may occur via enhancement of IL-6 production from antigen-presenting cells based on mouse studies [3234] . Human results demonstrated an essential role of IL-6 in the differentiation of TH17 cells [35] . In addition, GM-CSF-induced chemokine CCL22 may interact with CCR4 receptors expressed on T cells to enable the spreading of pathogenic T cells in RA patients [36] .
Recently, a reduced number of TH17 cells has been reported after macrophage depletion by an apoptosismediated therapy [37] . It is possible that chronic suppression of inflammatory cytokines and chemokines, such as IL-6 and CCL22, by mavrilimumab results in the suppression of TH17 cell activation and proliferation. CD4 + T cells are also a major source of GM-CSF in RA [38] . Whereas murine TH17 cells were identified as the chief producer of this cytokine, GM-CSF production in human was linked to TH1 cells and a subset of GM-CSF-only-producing T cells [39] . There is a positive feedback loop in RA, whereby GM-CSF secreted by RA synovial CD4 + T cells promoting inflammatory dendritic cells with potent capacity to enhance GM-CSF-producing T cells [38] . Mavrilimumab may disrupt this feedback loop in RA, resulting in a reduced activity of GM-CSF-producing CD4 + T cells.
The direct effects of mavrilimumab on myeloid cells and indirect impacts on T helper cells may both be responsible for the suppression of inflammatory mediators, such as MMPs, resulting in the improvement of tissue destruction. Type IV collagen is the main component of basement membrane that contributes to the structural organization of the synovia. Our results demonstrated that serum P4NP 7S level was associated with inflammatory markers (CRP and ESR), disease activity scores and joint damage levels in RA at baseline ( Table 1 ). The increased serum levels of P4NP 7S may reflect alterations in type IV collagen metabolism caused by synovitis in active RA [40] .
FIG. 4 Whole blood transcripts suppressed by mavrilimumab in ACR20 responders
Median log2-fold change at day 85 or 169 relative to pre-treatment in placebo-administered ACR20 responders (PBO R D85: n = 19; D169: n = 18) or non-responders (PBO NR D85: n = 33; D169: n = 46), and mavrilimumab-administered ACR20 responders (MAV R D85: n = 53; D169: n = 52) or non-responders (MAV NR D85: n = 18; D169: n = 17). BCL3, Bcell CLL/lymphoma 3; CCR1, chemokine receptor 1; CXCR1, IL-8 receptor a; IL17RA, IL-17 receptor A; ITGAX, integrin subunit alpha X; LCN2, lipocalin 2; NADK, NAD kinase; PAD2/4, peptidyl arginine deiminase type 2/4; PD-L1, programmed death-ligand 1; RARA, retinoic acid receptor a; SOCS3, suppressor of cytokine signalling 3; STAT3, signal transducer and activator of transcription 3; TREM1, triggering receptor expressed on myeloid cells 1.
Mavrilimumab treatment of 150 mg resulted in an early and sustained decline of P4NP 7S in clinical responders in comparison with non-responders. C1M is also associated with worsening joint structure in RA [41] . The suppression of both P4NP 7S and C1M in treatment responders suggested an improvement in joint function and a halt in tissue damage after GM-CSF blockade therapy.
In summary, our results demonstrated association of peripheral biomarker changes with therapeutic response to mavrilimumab in RA patients. Blockade of the GM-CSF pathway induced both direct downstream effects on myeloid cells and indirect impact on T cell activation, through which a sustained efficacy may be maintained for mavrilimumab treatment in RA patients.
